Getting back on track with improving cancer outcomes
1-2 October 2020
Draft Programme

Thursday 1 October 2020 Friday 2 October 2020
09:00 – 09:35

National update: Progress on delivering the Long Term Plan for cancer

  • Understand the impact of COVID-19 on work to improve cancer outcomes
  • Learn what needs to be done to get back on track with diagnosing cancer earlier and personalising treatment
  • Build systems and innovate to meet the challenges

Professor Peter Johnson, National Clinical Director for Cancer, NHS England and NHS Improvement

09:00 – 09:35

Diagnosis as a key element of recovery

  • Address the key elements needed in order to address demand and capacity for diagnosis
  • Explore the challenges and potential solutions to the need for more workforce, equipment and facilities
  • Approaching the challenge and doing things differently to improve capacity

Professor Mark Callaway, Medical Director, Professional Practice, Clinical Radiology, Royal College of Radiologists
Amelia Randle, Clinical Director, SWAG Cancer Alliance

09:35 – 09:45 Live Q&A 09:35 – 09:45 Live Q&A
09:45 – 10:00 Short break and session change 09:45 – 10:00 Short break and session change
10:00 – 10:30

Realistically, how can data ensure you help your population?

  • Learn what data is available across the UK and how you can use it to inform your work
  • How local and regional linked datasets can add insights to the national datasets
  • How to access and use real-time data to monitor and manage covid-19 service impact and recovery
  • Use integrated datasets to predict and prioritise those most at risk and take action on the backlog

Andi Orlowski, Deputy Director, Business Intelligence, Imperial College Health Partners, Senior Advisor Population Health Analytics, NHS England
James Peach, Commercial Director, DATA-CAN, the HDR UK Cancer Hub
Deb Lancaster, Head of Market Access Oncology,  Novartis
(Novartis has provided funding and input into the HSJ Cancer Virtual Forum and is a Key Partner of the event.)

10:00 – 10:30

Cell and Gene Therapies: What the future holds for cancer treatments

  • Learn what the achievements of cell and gene therapies are to date and how industry and healthcare systems partnered to bring CAR T to the UK
  • What the future holds for cell therapy and the insights on how clinical practice will benefit from the next generation of cell and gene therapies and how does the NHS prepare for such therapies
  • Offering hope in areas of high unmet need and what cell therapy means for patients with high unmet need
  • How we can put the patient voice at the heart of the discussion to ensure that patients that could benefit from cell and gene therapies are able to access them

Julian Cole, Medical Director, Gilead 
Dr Piers Patten, Clinical Senior Lecturer and Honorary Consultant Haematologist, King’s College Hospital Foundation Trust 
Gemma Peters, Chief Executive, Bloodwise 
(Session funded and developed by Kite, a Gilead Company)

10:30 – 10:40 Live Q&A 10:30 – 10:40 Live Q&A
10:40 – 10:55 Short break and session change 10:40 – 10:55 Short break and session change
10:55 – 11:25

How to improve pathways to ensure they are best for patients

  • Discuss how we ensure the most appropriate pathways are in place for patients in a peri- and post-COVID context
  • Learn how GIRFT methodology can be used to improve pathways and promotes QI solutions
  • Understand the opportunities with AI to improve cancer pathways
Stephen Hildrew, Regional Director Partnerships, Siemens Healthineers
Christof Kastner, Consultant Urologist, Addenbrookes Hospital
Fiona MacNeill, Clinical Lead, Breast Surgery, GIRFT
10:55 – 11:25

Rapid Diagnostic Centres in the context of covid-19

  • Learn about the impact of covid-19 on different models of RDC
  • What the increase in remote GP appointments and reduced capacity for testing means for the interface between primary and secondary care
  • What next? Explore how RDC methodology might evolve over the coming months and what this means for your work
Geraint Jones, Advanced Nurse Practitioner/Project Manager, Guy’s and St Thomas’ FT
Joe Mays, Lead for Prevention and Early Diagnosis, Peninsula Cancer Alliance
11:25 – 11:35 Live Q&A 11:25 – 11:35 Live Q&A
11:35 – 11:50 Short break and session change 11:35 – 11:50 Short break and session change
11:50 – 12:20

Practical strategies for the oncology workforce during COVID and beyond

  • Explore the impact on the oncology workforce of adapting to dynamic and uncertain circumstances
  • Discover how to remove the barriers to networked working, including governance agreements and ways of sharing information
  • Discuss recruitment and retention strategies for addressing the shortage of CNS
Jackie Fenemore, Chair, Lung Cancer Nursing UK
David Long, Oncology Business Unit Director, MSD
Sophia Nicola, Advisor for Primary Care, Macmillan Cancer Support
John Renninson, Clinical Lead, Peninsula Cancer Alliance
This session has been produced in collaboration between MSD and HSJ. MSD has funded for this session and is a key partner of the event.
11:50 – 12:30 Regaining patient confidence: The role of behavioural insights
  • Address the challenge of making people feel safe and confident to make and attend diagnostic appointments
  • Explore how to counteract the fear of being a burden on the NHS during the pandemic and encourage people to reach out with health concerns
  • Learn how to apply the EAST framework to encourage behaviour by making it easy, attractive, social and timely
Victoria Fussey, Senior Advisor, Health, Behavioural Insights Team
12:20 – 12:30 Live Q&A 12:20 – 12:30 Live Q&A
12:30 – 12:45 Short break and session change 12:30 – 12:45 Short break and session change
12:45 – 13:15

Horizon-scanning: What the next 12 months will hold

  • Receive an overview of the impact of COVID-19 on clinical trials, collaboration and development of new technology
  • Examine the range of opportunities and solutions for the coming year, including new technology, novel treatments and national work
  • Consider how we work to ensure that developments are to the benefit of all patients and not to the detriment of at risk or hard to reach groups
  • Discuss how to get to where we need to be in order to achieve national and local aims
Professor Rob Bristow, Director of Manchester Cancer Research Centre, The University of Manchester
Professor Berne Ferry, Head of the National School of Healthcare Science
Steve Williamson, Lead Cancer Pharmacist, NHS England and Improvement
12:45 – 13:25

Virtual Interactive Discussion Groups

How AI can assist cancer pathways
In association with Siemens Healthineers
No one left behind: Ensuring people come forward with cancer symptoms in a covid-19 world
In association with GSK
13:15 – 13:30 Live Q&A PM End of Live Sessions
Chat room remains open and 1-2-1 meetings take place
13:40 – 14:20 Virtual Interactive Discussion Groups
How AI can assist cancer pathways
In association with Siemens Healthineers
No one left behind: Ensuring people come forward with cancer symptoms in a covid-19 world
In association with GSK
PM End of Live Sessions
Chat room remains open and 1-2-1 meetings take place

Download Programme